云芝胞内多糖治疗高血脂症作用的临床观察

Effect of coriolus versicolor intracellular polysaccharide(CVICP) on blood lipid in patients with hyperlipidemia

目的临床研究云芝胞内多糖治疗高血脂症患者的疗效与安全性。方法我科门诊和住院的高血脂患者:胆固醇≥5.8mmol/L、TG≥2.4mmol/L者为入选对象,随机分成试验组1、2、3及安慰剂组,动态观测患者血脂的变化。结果云芝胞内多糖可显著降低高血脂患者血清胆固醇、甘油三酯及LDL水平,并能升高HDL的水平;对肝肾功能及血糖则无明显的影响。结论云芝胞内多糖对高血脂症有明显疗效,是一种安全的制剂。

Objective To evaluate the clinical efficacy and safety of coriolus versicolor intracellular polysaccharide（CVICP） for the treatment of patients with hyperlipidemia. Methods In this randomized, placebo-controlled trial, 480 patients with hyperlipidemia, total cholesterol（TC） ≥5.8mmol/L and triglyceride（TG） ≥2.4mmol/l, were divided into four groups： CVICP-treated 1,2, 3 groups and the control group. The levels of TC, TG, LDL-C cholesterol （LDL-C） were examined in all recipients before and after treatment. Results CVICP significantly decreased TC, TG, LDL-C and increased HDL-C,respectively. CVICP could protect from fatty liver-induced liver dysfunction. No obvious changes were seen in kidney function and plasma glucose level. Conclusion CVICP seemes to be safe and highly effective in treating hyperlipidemia.